Why Inovio Pharmaceuticals (INO) Stock Rose, Then Plunged Today (Update)

Update (4:25 p.m.): Updated with Tuesday market close information.

NEW YORK (TheStreet) -- Inovio Pharmaceuticals  (INO) surged Tuesday morning after the company started an immune therapy trial for head and neck cancer caused by HPV.

But the stock plunged in the afternoon after TheStreet's Adam Feuerstein wrote CEO Joseph Kim is trying to curb expectations for the soon-to-be-announced results from its phase II study of its DNA vaccine VGX-3100 in women with cervical pre-cancerous lesions.

The stock closed down 13.36%, or $1.44, to $9.34. More than 11.3 million shares changed hands, which surpassed the average volume of 1,521,180.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

For more on this story, read Feuerstein's article here.

INO Price Chart

INO Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Investors Need to Closely Watch Mario Draghi's Speech at Jackson Hole: Market Recon

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round

These Stocks Are Ready to Reverse Course

Biotech Movers: Sarepta, Inovio, Mylan